CIRRUS-2023-1: Evaluating PathFinder 1.0 for Macular Abnormalities
This study is testing a new software called PathFinder 1.0. This software analyzes images from a common eye scan called an OCT (Optical Coherence Tomography) to find problems in the macula (the central part of your retina responsible for sharp vision). We want to see how accurately PathFinder 1.0 can detect conditions like epiretinal membrane and dry age-related macular degeneration. You would have a standard OCT scan, and the software would analyze the images without changing your regular eye care. We are looking for about 400 adults, aged 18 and older, who are able to complete eye imaging and study visits. The study is currently unclear on its recruitment status.
- Study design
- This is an interventional study involving about 400 participants. It is designed to measure the sensitivity and specificity of PathFinder 1.0.
- What's involved
- You would need to attend required study visits and complete ophthalmic imaging. The primary endpoints are measured at a single study visit for OCT acquisition.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
At a glance
Conditions
Where it's being run
6 sites across 5 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Sensitivity of PathFinder 1.0Baseline (single study visit OCT acquisition)
Sensitivity is the proportion of scans that PathFinder 1.0 correctly identifies as having any macular abnormality.
- Specificity of PathFinder 1.0Baseline (single study visit OCT acquisition)
Specificity is the proportion of scans that PathFinder 1.0 correctly identifies as having no macular abnormality.